Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04652908
Other study ID # 1617774
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date June 21, 2021
Est. completion date March 2024

Study information

Verified date September 2023
Source University of California, Davis
Contact Maria G Hernandez, CPT1
Phone 916-734-4156
Email mghernandez@ucdavis.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Spina bifida, or myelomeningocele (MMC), is a disorder where the lower part of the spinal cord of the fetus is exposed, meaning there is no bone or skin covering it. This is dangerous because the spinal cord contains cells which control one's ability to move their legs and walk, and also to be able to urinate and have bowel movements normally. One of the current treatments for fetal MMC is to perform a surgery on the fetus before it is born which has many names including in utero surgery, prenatal surgery, or fetal surgery. This is a surgery that occurs inside the uterus (the womb) where the surgeon closes the opening in your fetus' back to cover the exposed spinal cord. Researchers have found that adding stem cells to the repair is effective in improving the ability of animals with MMC to walk, and that the stem cells are safe in animal studies. These stem cells are thought to protect the cells in the spinal cord that control movement and developmental outcomes. This study is being performed to look at the safety and effectiveness of stem cells on the fetus's exposed spinal cord during prenatal surgery.


Description:

Historically, treatment of MMC was limited to post-natal surgery to close the dura and skin over the spinal cord to prevent meningitis, which had no effect on motor function. The potential benefit of earlier intervention was realized when prenatal ultrasound of patients with MMC early in gestation revealed near-normal leg movements despite displaying paralysis at birth. This finding gave credence to the two-hit hypothesis that paralysis was progressive during prenatal life and suggested that fetal intervention could prevent the secondary damage to the spinal cord. Fetal repair of MMC did confer improvement in motor function of children treated in the Management of Myelomeningocele (MOMS) randomized controlled trial. The promising results of the MOMS trial demonstrated the potential for improvement of paralysis for these patients, but distal motor function still remained severely impaired in the majority of patients with MMC with standard in utero repair alone. While this demonstrated that the ideal time to intervene to prevent paralysis is in utero with the goal of preventing the accrual of ongoing damage to the spinal cord, there is still room for improvement. The remarkable regenerative capacity of the fetal environment combined with regenerative capacity of placental mesenchymal stem cells offers potential for augmentation of the fetal repair of MMC with a novel therapy to further reduce and repair the sustained spinal cord damage.


Recruitment information / eligibility

Status Recruiting
Enrollment 55
Est. completion date March 2024
Est. primary completion date March 2024
Accepts healthy volunteers No
Gender All
Age group 19 Weeks to 25 Weeks
Eligibility Inclusion Criteria: Eligibility for fetal surgery per the MOMS trial, which are: - Myelomeningocele (including myeloschisis) at any level from T1 through S1 with hindbrain herniation. Lesion level will be confirmed by ultrasound and hindbrain herniation will be confirmed by MRI at the UC Davis Fetal Center - Maternal age =18 years - Gestational age at enrollment between 19 weeks 0 days and 25 weeks 6 days gestation as determined by clinical information and evaluation of first ultrasound - Normal karyotype. Results by fluorescence in situ hybridization (FISH) will be acceptable if the patient is greater than 24 weeks gestation; Exclusion Criteria: Not being eligible for fetal surgery per the MOMS trial, which includes: - Multifetal pregnancy - Insulin dependent pregestational diabetes - Fetal anomaly not related to myelomeningocele. - Kyphosis in the fetus of 30 degrees or more - Current or planned cerclage or documented history of incompetent cervix, placenta previa or placental abruption - Short cervix < 20 mm measured by cervical ultrasound - Obesity as defined by body mass index of 35 or greater - Previous spontaneous singleton delivery prior to 37 weeks - Maternal-fetal Rh isoimmunization, Kell sensitization or a history of neonatal alloimmune thrombocytopenia - Maternal HIV or Hepatitis-B status positive due to the increased risk of transmission to the fetus during maternal-fetal surgery. If the patient's HIV or Hepatitis B status is unknown, the patient must be tested and found to have negative results before she can be enrolled - Known Hepatitis-C positivity. If the patient's Hepatitis C status is unknown, she does not need to be screened - Uterine anomaly such as large or multiple fibroids or Müllerian duct abnormality - Other maternal medical condition which is a contraindication to surgery or general anesthesia. This includes any patient with a previous hysterotomy in the active segment of the uterus (whether from a previous classical cesarean, uterine anomaly such as an arcuate or bicornuate uterus, major myomectomy resection, or previous fetal surgery) - Patient does not have a support person (e.g., husband, partner, mother) - Inability to comply with the travel and follow-up requirements of fetal surgery - Patient does not meet other psychosocial criteria (as determined by the psychosocial interviewer) to handle the implications of fetal surgery - Participation in another intervention study that influences maternal and fetal morbidity and mortality or participation in this trial in a previous pregnancy; - Maternal hypertension which would increase the risk of preeclampsia or preterm delivery (including, but not limited to: uncontrolled hypertension, chronic hypertension with end organ damage and new onset hypertension in current pregnancy) - Active COVID-19 infection at time of fetal surgery as determined by positive test

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Placental Mesenchymal Stem Cells seeded on a commercially available dural graft extracellular matrix
As in the current standard fetal surgery, under sonographic guidance, initial uterine entry will be accomplished by uterine stapling device or similar. The fetus will be given an intramuscular injection of pain medications and paralytic. The myelomeningocele will be closed in a standardized manner under magnification. As in the standard fetal operation, the spinal cord will be dissected from surrounding tissue and allowed to drop into the spinal canal. The PMSC-ECM product will then be tailored to the size of the spinal cord and applied topically, cell side down. The PMSC-ECM product will be sutured in place to the dura. Finally, the fetal skin will be closed in the standard fashion. The amniotic fluid volume will be replaced and antibiotics will be added. The uterus will be closed. The abdominal fascial layer and skin will be closed in routine fashion.
Other:
Untreated contemporaneous cohort
The addition of a non-PMSC treated cohort, the untreated contemporaneous cohort, has been added at the request of the FDA to provide contemporaneous patients for validation of the continued relevance of use of the outcomes of the MOMS trial as the comparison arm for the Phase 2a portion of the study.

Locations

Country Name City State
United States UC Davis Health Sacramento California

Sponsors (2)

Lead Sponsor Collaborator
Diana Lee Farmer California Institute for Regenerative Medicine (CIRM)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety of the placenta-derived mesenchymal stem cell (PMSC-ECM) Product Will be assessed by evaluating the presence or absence of cerebrospinal fluid leak, infection at the MMC repair site, failure of the MMC repair site to heal, and any unexpected growths or tumor formation. These will be assessed at birth by physical exam, brain and spinal ultrasound , and brain and spinal MRI. Assessed at birth
Secondary Efficacy of the PMSC-ECM Product This is primarily evaluated by improvement in motor function 2 or more levels greater than expected by anatomic level of the defect and by patients' ability to walk independently. Bowel function will be assessed by caregiver questionnaires on bowel habits, and by anorectal manometry. Urologic function will be assessed by caregiver questionnaires regarding urologic function, by renal and bladder ultrasounds to evaluate for hydronephrosis and bladder abnormalities, and by video urodynamics. 30 months.
See also
  Status Clinical Trial Phase
Recruiting NCT06042140 - Cryopreserved Human Umbilical Cord as a Meningeal Patch in Fetoscopic Spina Bifida Repair N/A
Recruiting NCT03562286 - Open Spina Bifida Fetoscopic Repair Project N/A
Completed NCT04468568 - In Utero Repair of Myelomeningocele: Atosiban Versus Terbutaline
Recruiting NCT04362592 - In-Utero Endoscopic Correction of Spina Bifida N/A
Recruiting NCT03856034 - Laparotomy Versus Percutaneous Endoscopic Correction of Myelomeningocele N/A
Active, not recruiting NCT03936322 - Minimally Invasive Fetoscopic Regenerative Repair of Spina Bifida - A Pilot Study N/A
Not yet recruiting NCT06405698 - Role of Perforator Flaps in Back Defects Reconstruction N/A
Active, not recruiting NCT00175123 - Effect of Botulinum Toxin in Neurogenic Bladders in Children With Myelomeningocele Phase 4
Completed NCT02390895 - Prenatal Endoscopic Repair of Fetal Spina Bifida N/A
Active, not recruiting NCT03090633 - Fetoscopic Repair of Isolated Fetal Spina Bifida N/A
Not yet recruiting NCT03088761 - Cuff Pressure in Infants N/A
Active, not recruiting NCT04484441 - Maternal-fetal Immune Responses to Fetal Surgery
Recruiting NCT04738539 - Efficacy of Contrast Enhanced Voiding Urosonography for Urodynamic Studies
Terminated NCT02493062 - Evaluation of Hysterotomy Site After Open Fetal Surgery N/A
Completed NCT03550898 - Can Dynamic Ultrasonography Replace Urodynamics in Follow-up of Patients With Myelomeningocele N/A
Active, not recruiting NCT04251806 - Sleep-disordered Breathing in Infants With Myelomeningocele
Terminated NCT02509377 - Fetal Myelomeningocele Repair With Maternal BMI Between 35.0 and 40.0 N/A
Recruiting NCT03788122 - Fetal Surgery Interview Study: Parental Perceptions of Fetal Surgery N/A
Completed NCT02664207 - Extended Criteria For Fetal Myelomeningocele Repair N/A
Recruiting NCT03315637 - Fetal Endoscopic Surgery for Spina Bifida N/A